NCT06817382View on ClinicalTrials.gov

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 22, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

March 31, 2028

Conditions

Duchenne Muscular Dystrophy

Interventions

GENETIC

INS1201

Suspension for IT injection.

Trial Locations (6)

14642

RECRUITING

USA008, Rochester

30329

RECRUITING

Rare Disease Research (USA004), Atlanta

38105

RECRUITING

USA001, Memphis

72202

RECRUITING

USA012, Little Rock

94070

RECRUITING

USA002, Palo Alto

95616

RECRUITING

USA010, Davis

All Listed Sponsors

lead

Insmed Gene Therapy LLC

INDUSTRY

NCT06817382 - A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter